Rezolute, Inc. Segments Disclosure
NOTE 15 — SEGMENT DISCLOSURES
The Company has determined that it operates as a reportable segment which includes all of its activities as a clinical stage biopharmaceutical company. The CODM uses consolidated net loss as reported on the consolidated statement of operations to assess performance, analyze budget to actual results, forecast future periods, and allocate resources for its single reportable segment. The significant segment expenses regularly reviewed by the CODM consist of clinical and manufacturing costs of the Company's product candidates, personnel expenses, and other segment expenses. The measure of the operating segment assets is reported on the consolidated balance sheet as total assets and all of the Company's tangible assets are located in the United States.
The following table presents consolidated net loss summarized by the significant segment expenses regularly reviewed by the CODM for the years ended June 30, 2025, and 2024 (in thousands):
2025 |
| 2024 | |||
Research and development: |
| ||||
Ersodetug | $ | 31,752 | $ | 19,937 | |
RZ402 | 601 | 7,648 | |||
Compensation and benefits | 19,404 | 17,463 | |||
Other R&D segment expenses (1) | 9,770 | 10,695 | |||
Total research and development |
| 61,527 | 55,743 | ||
General and administrative: |
| ||||
Compensation and benefits | 10,756 | 8,933 | |||
Other G&A segment expenses (2) | 7,611 | 5,747 | |||
Total general and administrative |
| 18,367 | 14,680 | ||
Operating loss | (79,894) | (70,423) | |||
Total non-operating income (expense), net | 5,482 | 1,964 | |||
Net loss | $ | (74,412) | $ | (68,459) | |
| (1) | Other R&D segment expenses primarily include licensing costs, quality regulatory and other pipeline development costs, employee travel and expense, and other facility and information technology costs. |
| (2) | Other G&A segment expenses primarily include consulting expenses related to business development and market planning activities, employee travel and expense, insurance expense, public company costs, and other facility and information technology costs. |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.